To evaluate Neoadjuvant chemotherapy in treatment of unresectable cervical cancer patients
Phase 2
Recruiting
- Conditions
- cancer of cervix.Malignant neoplasm of cervix uteri
- Registration Number
- IRCT20210808052110N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 74
Inclusion Criteria
1.Unresectable cervical cancer(IIB toIVA,IB3,IIAmore than 4cm)
2.No history of metastasis
3.Adequate renal function(GFR more than 60ml per min per1.73)
4.Adequate hepatic function(Liver enzyme<5* upper limit normal)
5.Adequate bone marrow function(Absolute neutrophil>1500)
6-Without history of systemic disease
7.Absence of active infection
8.Absence of previous or concurrent oncology pathology
9.ECOG performance status 0 and 1
10.Age 18 to 75 years
Exclusion Criteria
1-Previous pelvic radiation
2-Pregnancy
3-Serious medical illness
4-Hypersensitivity to chemotherapy agent
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment 3 months after fulfilling it. Timepoint: 3 months after fulfilling treatment. Method of measurement: To do MRI and evaluate response to treatment by recist 1.1 guideline.
- Secondary Outcome Measures
Name Time Method